Hearn, W. L., Mash, D.C., Pablo, J., Hime, G., Sambol, N.C., and Doepel, F.M. Pharmacokinetics of Ibogaine: Analytical method, animal-human comparisons, and the identification of a primary metabolite. Proceedings of the TIAFT-SOFT Joint Congress, Oct. 21 – Nov. 4, 1994 (Spiehler, V. ed.) Omnipress, Ann Arbor, MI, pp. 325 – 334, 1995.


Mash, D.C., Staley, J.K., Baumann, M., Rothman, R.P., and Hearn, W.L., Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Pharmacol. Letters 57: 45-50, 1995.


Mash, D.C., Pablo, J., Staley, J. K., Holohean, A.M., Hackman, J.C., and Davidoff, R.A., Properties of Ibogaine and a principal metabolite (12-Hydroxyibogamine) at the MK-801 binding site on the NMDA- receptor complex. Neurosci. Letters 192:53-56, 1995.


Hearn, W.L., Pablo, J., Hime, G. and Mash, D.C. Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography/mass spectrometry. J. Anal. Tox. 19:427-434, 1995.


Mash, D.C., Douyan, R., Hearn, W.L., Sambol, N.C., Sanchez-Ramos, J.  A preliminary report on the safety and pharmacokinetics of ibogaine. Biol. Psych.  37: 652, 1995.


Staley, J.K., Ouyang, Q, Pablo, J., Hearn , W.L., Flynn, D.D., Rothman, R.B.,  Rice, K.C. Mash, D.C., Pharmacological screen for activities of 12-hydroxyibogamine: A primary metabolite of the indole alkaloid ibogaine. Psychopharm 127:10-18, 1996.


Sanchez-Ramos, J. and Mash, D. C. Pharmacotherapy of drug dependence with Ibogaine, IN: Constructive Potential of Psychedelics: Cross-Cultural Perspectives, (Winkelman, M., and Andritzky, W., eds.) Yearbook of Cross-Cultural Medicine and Psychotherapy, Berlin, pp. 353- 367, 1996.


Efange, S.M.N., Mash, D.C., Khare, A.B., Ouyang, Q. Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5,6 hexahydroazepino [4,5-b] benzothiophenes.  J. Med. Chem. 41(23):4486-91, 1998.


Pablo, J. and Mash, D.C. Noribogaine stimulates naloxone-sensitive [35S]GTPgS binding. NeuroReport 9:109-114, 1998.


Obach, R. S., Pablo, J. and Mash, D.C. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metabolism and Disposition 25(12):1359-69, 1998.


Mash, D.C., Kovera, C. A., Buck, B.E., Norenberg, M.E., Shapshak, P., Hearn, W.L. and Sanchez-Ramos, J. Medication development of Ibogaine as a pharmacotherapy for drug dependence,  (ed. Sayed Ali),  Ann. New York Academy of Sciences, 844:274-292, 1998.


Zubaran, C., Shoaib, M., Stolerman, I.P., Pablo, J., Mash, D.C., Noribogaine generalization to the ibogaine stimulus: Correlation with noribogaine concentration in rat brain. Neuropsychopharmacology 21: 119-126, 1999.


Mash, D.C., Kovera, C.A., Pablo, J., Tyndale, F.R., Ervin, F.D., Williams, I.C., Singelton, E.G., Mayor, Manny. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.  Ann New York Acad Science, 914:394-401, 2000.


Baumann, M.H., Rothman, R.B., Pablo, J.P., Mash, D.C. In vivo neurobiological effects of ibogaine and its o-Des-methyl metabolite, 12-hydroxyibogamine (Noribogaine), in rats. J. Pharm. Exp. Ther. 297(2):531-539, 2001.


Mash, D.C., Kovera, C.A., Pablo, J., Tyndale, R., Ervin, F.R., Kamlet, J.D., Hearn, W. L. Ibogaine in the treatment of heroin withdrawal. In: Ibogaine: Proceeding of the first International Conference., Alkaloid Series, Volume 56. Editors: Dr. Kenneth Alper and Dr. Stan Glick. Academic Press, San Diego, California pp 156-170, 2001.


Baumann, M.H., Pablo, J., Ali, S.F., Rothman, R.B., Mash, D.C. Comparative neuropathology of ibogaine and its o-desmethyl metabolite, noribogaine. In: Ibogaine: Proceeding of the First International Conference., Alkaloid Series, Volume 56.  Editors: Dr. Kenneth Alper and Dr. Stan Glick. Academic Press, San Diego, California pp 80-109, 2001.


Pasarella, D., Favia, R., Giardini, A., Lessma, G., Martinelli, M., Silvani, A., Danieli, B., Efange, S.M.N., and Mash, D.C. Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo [2.2.2] Oct-7-enes. Biorg. Med. Chem. 11(6):1007-14, 2003.


Mash, D.C. Ibogaine Therapy. Euro Neuropsychopharm 15(3):S322, 2005.


Passarella, D., Barilli, A., Efange, S.M.N., Elisabetsky, E., Leal, M.B., Lesma, G., Linck, V.M., Mash, D.C., Martinelli, M., Peretto, H., Silvani, A., Danieli, B. Nature-inspired indolyl-2-azabicyclo [2.2.2] act-7-ene derivatives as promising agents for the attention of withdrawal symptoms. Synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine. Nat Prod Res 20(8):758-65, 2006.


Mash DC. Ibogaine therapy for substance abuse disorders: Clinical Addition Psychiatry: (Part 1, Chapter 6). Editors: Brizer, D. and Castaneda, R., Cambridge University Press, 2010.


Chang Q, Hanania T, Mash DC, Maillet E. Noribogaine reduces nicotine self-administration in rats. J  Psychoparmacol. 29(6): 704-711. DOI: 10.1177/026988115584461. 2015.


Maillet E, Chang Q, Milon N, Hanania T, Heghinian M, Garamszegi N, Mash DC. Characterization of Noribogaine at nAChRs and Effect on Nicotine Self-Administration in Rats. J. Psychopharmacol. (6): 704-11. DOI: 1019.2. 2015.


Maillet EL, Milon N, Heghinian MD, Fishback J, Schurer SC, Garamszegi N, Mash DC. Noribogaine is a G-protein  biased k-opioid receptor agonist. Neuropharmacology. 2015 Dec; 99:675-88. DOI: 10.1016.


Mash DC, Ameer B, Prou D, Howes JF, Maillet EL Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. J Psychopharmacol. 2016 Jul; 30(7):688-97. doi: 10.1177/0269881116641331. Epub 2016 Apr 4. PMID: 27044509


Mash DC Breaking the cycle of opioid use disorder with Ibogaine.

Am J Drug Alcohol Abuse. 2018;44(1):1-3. doi: 10.1080/00952990.2017.1357184. Epub 2017


Mash DC, Duque L, Page B, Ferdinand KA Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes.  Frontiers Psychopharmacology published: 05 June 2018 doi: 10.3389/fphar.2018.00529